Business

Insilico Medicine Lands $2.75 Billion Deal with Eli Lilly to Commercialize AI-Designed Drugs

March 29, 2026 · From the archive, written in the Professor's voice before our October 2026 redesign from statnews.com

What happened

Insilico Medicine, a pioneer in AI-driven drug discovery, inked a partnership with Eli Lilly valued at up to $2.75 billion, including an upfront $115 million payment. The deal hinges on Insilico’s proprietary generative chemistry algorithms and deep learning models to identify novel pharmaceutical compounds.

Why it matters

This deal exemplifies how AI-generated molecular design is transitioning from lab experiments to commercial-scale drug development. It underlines the growing trust pharmaceutical giants place in generative chemistry and deep learning to accelerate candidate identification, reducing time and cost compared to traditional methods.

Who's doing it

Insilico Medicine and Eli Lilly are at the forefront, with Insilico’s AI platform reportedly cutting drug candidate discovery timelines by up to 50%. Their collaboration sets a new industry benchmark for AI integration in drug commercialization.

Try it

1. Access Insilico Medicine’s AI platform (https://insilico.com).
2. Input desired target protein or disease parameters to generate candidate molecules using their generative chemistry tool.
3. Analyze AI-predicted efficacy and safety profiles to shortlist compounds for experimental validation, expecting a streamlined discovery phase.

Read the original at statnews.com